📊 BNGO Key Takeaways
Is Bionano Genomics, Inc. (BNGO) a Good Investment?
Bionano Genomics is a pre-revenue/early-stage company with severe profitability issues, burning significant cash while generating minimal revenue that is declining year-over-year. The company faces an existential challenge with negative operating margins of -120.7% and operating cash burn of -$12.2M annually, while cash reserves of only $3.1M provide limited runway.
Bionano Genomics shows weak fundamentals: revenue is declining, operating losses remain larger than revenue, and free cash flow is deeply negative. The balance sheet benefits from no long-term debt and acceptable near-term liquidity, but the very low cash balance relative to ongoing cash burn raises significant financing and going-concern risk unless operating performance improves materially.
Why Buy Bionano Genomics, Inc. Stock? BNGO Key Strengths
- Zero long-term debt provides financial flexibility without debt service obligations
- Adequate liquidity with 2.12x current ratio and $3.1M cash suggests short-term solvency
- Operating in laboratory analytical instruments sector with potential market opportunities if technology gains adoption
- No long-term debt, which reduces balance sheet leverage risk
- Current and quick ratios indicate near-term liabilities are still covered
- Negative EPS improved year over year, suggesting some cost or share-count-related improvement
BNGO Stock Risks: Bionano Genomics, Inc. Investment Risks
- Severe cash burn of -$12.2M annually with only $3.1M in cash reserves implies approximately 3 months of runway at current burn rates
- Revenue declining 14.8% YoY while operating losses widen, indicating deteriorating business fundamentals and lack of market traction
- Negative net margin of -89.8% and ROE of -37.1% demonstrate the company is destroying shareholder value and not achieving profitability milestones
- High insider trading activity (10 Form 4 filings in 90 days) may suggest management uncertainty or position adjustments
- Revenue declined 14.8% year over year, indicating weak growth quality and limited commercial traction
- Operating margin of -120.7% and net margin of -89.8% show the business model is far from profitable
- Cash of $3.06M versus negative operating cash flow of $12.17M implies substantial liquidity pressure and likely need for external capital
Key Metrics to Watch
- Cash runway and path to cash flow breakeven given current burn rate
- Revenue trajectory and ability to reverse YoY decline
- Operating expense reduction and progress toward operating profitability
- Quarterly revenue growth and evidence of sustained commercial adoption
- Cash burn runway, especially operating cash flow and ending cash balance
Bionano Genomics, Inc. (BNGO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.12x current ratio provides a solid financial cushion.
BNGO Profit Margin, ROE & Profitability Analysis
BNGO vs Industrial Sector: How Bionano Genomics, Inc. Compares
How Bionano Genomics, Inc. compares to Industrial sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bionano Genomics, Inc. Stock Overvalued? BNGO Valuation Analysis 2026
Based on fundamental analysis, Bionano Genomics, Inc. has mixed fundamental signals relative to the Industrial sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bionano Genomics, Inc. Balance Sheet: BNGO Debt, Cash & Liquidity
BNGO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bionano Genomics, Inc.'s revenue has grown significantly by 71% over the 5-year period, indicating strong business expansion. The most recent EPS of $-88.13 indicates the company is currently unprofitable.
BNGO Revenue Growth, EPS Growth & YoY Performance
BNGO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.1M | -$3.1M | $-1.59 |
| Q2 2025 | $6.7M | -$3.1M | $-1.99 |
| Q1 2025 | $6.5M | -$3.1M | $-1.15 |
| Q3 2024 | $6.1M | -$16.2M | $-0.52 |
| Q2 2024 | $7.8M | -$16.2M | $-0.24 |
| Q1 2024 | $7.4M | -$31.4M | $-0.60 |
| Q3 2023 | $7.2M | -$30.0M | $-1.10 |
| Q2 2023 | $6.7M | -$30.0M | $-1.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bionano Genomics, Inc. Dividends, Buybacks & Capital Allocation
BNGO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bionano Genomics, Inc. (CIK: 0001411690)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNGO
What is the AI rating for BNGO?
Bionano Genomics, Inc. (BNGO) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNGO's key strengths?
Claude: Zero long-term debt provides financial flexibility without debt service obligations. Adequate liquidity with 2.12x current ratio and $3.1M cash suggests short-term solvency. ChatGPT: No long-term debt, which reduces balance sheet leverage risk. Current and quick ratios indicate near-term liabilities are still covered.
What are the risks of investing in BNGO?
Claude: Severe cash burn of -$12.2M annually with only $3.1M in cash reserves implies approximately 3 months of runway at current burn rates. Revenue declining 14.8% YoY while operating losses widen, indicating deteriorating business fundamentals and lack of market traction. ChatGPT: Revenue declined 14.8% year over year, indicating weak growth quality and limited commercial traction. Operating margin of -120.7% and net margin of -89.8% show the business model is far from profitable.
What is BNGO's revenue and growth?
Bionano Genomics, Inc. reported revenue of $20.6M.
Does BNGO pay dividends?
Bionano Genomics, Inc. does not currently pay dividends.
Where can I find BNGO SEC filings?
Official SEC filings for Bionano Genomics, Inc. (CIK: 0001411690) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNGO's EPS?
Bionano Genomics, Inc. has a diluted EPS of $-4.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BNGO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bionano Genomics, Inc. has a STRONG SELL rating with 91% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BNGO stock overvalued or undervalued?
Valuation metrics for BNGO: ROE of -37.1% (sector avg: 15%), net margin of -89.8% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy BNGO stock in 2026?
Our dual AI analysis gives Bionano Genomics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BNGO's free cash flow?
Bionano Genomics, Inc.'s operating cash flow is $-12.2M, with capital expenditures of $344.0K. FCF margin is -60.9%.
How does BNGO compare to other Industrial stocks?
Vs Industrial sector averages: Net margin -89.8% (avg: 10%), ROE -37.1% (avg: 15%), current ratio 2.12 (avg: 1.8).